Abstract #1268

Koutcher J, Rosen N, Lupu M, Matei C, Solit D, Le H

Hsp90 inhibitor 17AAG is being studies as a chemotherapy agent against prostate cancers. It has been shown to cause tumor growth arrest and partial shrinkage. Using total choline as a tumor proliferation surrogate maker, we compare the metabolic response of the hormone sensitive and resistant human prostate cancer CWR22 after 17AAG treatment. Differential responses of the two cancer lines shows that 17AAG can be a promising agent for the resistant line and that 1H MRS is a sensitive technique for tumor monitoring.